News
TELA
1.260
-0.79%
-0.010
Craig-Hallum Initiates Coverage of TELA Bio at Buy
NASDAQ · 2d ago
TELA Bio Price Target Announced at $2.00/Share by Craig-Hallum
Dow Jones · 2d ago
Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2
Benzinga · 2d ago
Craig-Hallum bullish on Tela Bio, initiates with a Buy
TipRanks · 2d ago
Tela Bio initiated with a Buy at Craig-Hallum
TipRanks · 2d ago
Weekly Report: what happened at TELA last week (0914-0918)?
Weekly Report · 09/21 09:17
TELA Bio Faces Nasdaq Delisting, Plans Reverse Split
TipRanks · 09/18 20:35
Analysts Offer Insights on Healthcare Companies: TELA Bio (TELA), Oscar Health (OSCR) and Brookdale Senior Living (BKD)
TipRanks · 09/17 13:40
Weekly Report: what happened at TELA last week (0907-0911)?
Weekly Report · 09/14 09:18
Weekly Report: what happened at TELA last week (0831-0904)?
Weekly Report · 09/07 09:16
Analysts’ Top Healthcare Picks: Argenx Se (ARGX), TELA Bio (TELA)
TipRanks · 09/03 13:20
Analyst Reaffirms Buy on TELA Bio, Citing Restructuring-Driven Cost Savings and Steady $2 Price Target
TipRanks · 09/01 12:35
Morning Movers: SAIC jumps following FY27 guidance hike
TipRanks · 08/31 12:55
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/31 12:50
TELA Bio Implements Workforce Cuts and Leadership Changes
TipRanks · 08/31 11:28
TELA Bio Announces $17M Annual Expense Reduction Through 20% Workforce Streamlining and Resource Optimization, Extending Cash Runway Into 2028
Benzinga · 08/31 11:10
TELA Bio COO And CFO Roberto Cuca To Step Down Effective Immediately
Benzinga · 08/31 11:09
*TELA Bio Oper Chief and Chief Fincl Officer Roberto Cuca to Step Down From the Roles
Dow Jones · 08/31 11:04
Press Release: TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Dow Jones · 08/31 11:00
Weekly Report: what happened at TELA last week (0824-0828)?
Weekly Report · 08/31 09:18
More
Webull provides a variety of real-time TELA stock news. You can receive the latest news about Tela Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TELA
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The Company's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.